Focused Ultrasound and Ablative Neurosurgery

What it is

This document covers the two ends of a single conceptual spectrum: deliberately destroying a small volume of brain tissue to interrupt a pathological circuit (ablative neurosurgery), and the emerging, incisionless technology that increasingly performs that ablation — and may eventually replace it with reversible neuromodulation (focused ultrasound). They belong together because magnetic-resonance-guided focused ultrasound is the modern, non-incisional way to create the same therapeutic lesions that stereotactic neurosurgery has made for decades, while low-intensity focused ultrasound points toward a future in which deep structures can be modulated without any lesion at all. Together they represent the most invasive irreversible intervention in psychiatry and one of its most intriguing frontiers, separated by the dose of acoustic energy delivered.

Ablative neurosurgery: history and present

Psychiatric neurosurgery carries a heavy historical burden. The crude prefrontal lobotomy of the mid-twentieth century — indiscriminate, unmeasured, and applied at scale — is among the field's gravest ethical failures, and any honest account must name it. Modern stereotactic ablation is a categorically different enterprise: small, precisely placed, image-guided lesions targeting specific tracts, applied only to the most extreme refractory illness under stringent multidisciplinary ethical review. The distinction between lobotomy and contemporary stereotactic surgery is not a matter of degree but of kind, and conflating them does a disservice to patients who have exhausted every alternative.

Four procedures define the modern repertoire, all targeting fronto-limbic and fronto-striatal circuitry: anterior cingulotomy, subcaudate tractotomy, limbic leucotomy (a combination of the two), and anterior capsulotomy. Their principal indication is severe, chronic, treatment-refractory obsessive-compulsive disorder, with treatment-resistant depression a secondary indication. The evidence base is necessarily limited — these are rare procedures, difficult to randomize or sham-control — but careful open series report meaningful response in 40–60% of otherwise intractable OCD patients (Dougherty; Greenberg; Rück and colleagues), a notable figure in a population defined by having failed everything else.

Modern ablation modalities

How the lesion is created has evolved substantially. Radiofrequency thermal ablation delivers heat through a stereotactically placed probe — precise but requiring a burr hole and probe insertion. Gamma knife radiosurgery (gamma ventral capsulotomy) creates a lesion non-incisionally using focused gamma radiation, at the cost of a delayed effect that unfolds over months and the considerations attending ionizing radiation.

The most important advance is MR-guided focused ultrasound (MRgFUS), which focuses acoustic energy through the intact skull to heat and ablate a small deep target, with real-time MRI thermometry confirming the lesion as it forms — no incision, no radiation, no implanted hardware. MRgFUS is FDA-approved for essential tremor and is established in functional neurosurgery; its application to psychiatric capsulotomy for refractory OCD and depression is investigational but advancing (Kim, Jung, and colleagues), and it represents the most patient-acceptable way yet devised to perform an ablative psychiatric procedure.

The frontier: low-intensity focused ultrasound neuromodulation

A fundamentally different use of ultrasound is the most genuinely novel idea in this series. Low-intensity focused ultrasound (LIFU) uses acoustic energy below the threshold for tissue damage to reversibly modulate neural activity — neither lesioning nor implanting. Its distinctive promise is spatial: ultrasound can be focused on deep targets (the amygdala, thalamic nuclei, subgenual regions) with far better spatial resolution and depth than TMS or tDCS, which are limited to cortical surface effects. If realized, LIFU would offer something no current modality provides — non-invasive, reversible, anatomically precise modulation of the deep structures that DBS can reach only surgically. The work is early, largely confined to healthy-volunteer and small pilot studies (Legon, Sanguinetti, and colleagues), and its therapeutic value in psychiatry is unproven — but the concept is the most important long-horizon development the series contains.

How it works

The two modes are mechanistically opposite. Ablation produces a permanent disconnection: capsulotomy, for instance, interrupts the fronto-thalamic and fronto-striatal fibers running through the anterior limb of the internal capsule, severing the overactive cortico-striato-thalamo-cortical loop implicated in OCD. LIFU neuromodulation, by contrast, transiently alters neuronal excitability — likely through mechanical effects on ion channels — without structural damage, an effect that switches off when stimulation stops. The same targets implicated across this library's DMN and reward-circuit accounts are addressed by both, in one case by destruction and in the other by reversible perturbation.

The convergence

This pair anchors the irreversible extreme of the interventional spectrum while pointing toward its non-invasive future. Ablative capsulotomy targets the same VC/VS circuitry as DBS — the natural and important contrast being reversibility: DBS modulates and can be switched off, whereas a lesion is permanent, a difference that increasingly favors stimulation where both are options. LIFU, at the other pole, would extend the non-invasive logic of TMS and tDCS to the deep targets they cannot reach, potentially collapsing the long-standing trade-off between reach and invasiveness that organizes this entire series.

Caveats — load-bearing, not decorative

Irreversibility is the defining caveat of ablation, as above. Second, the historical and ethical legacy of psychosurgery demands that these procedures be reserved for the most extreme, exhaustively refractory cases, performed only under rigorous independent ethical review with fully informed consent — and that the modern, precise procedures be clearly distinguished from the abuses of the lobotomy era without using that distinction to minimize the stakes. Third, the evidence base is limited: open series rather than randomized sham-controlled trials, reflecting the genuine difficulty of controlling surgical interventions. Fourth, for LIFU specifically, enthusiasm must be tempered by the reality that its therapeutic efficacy in psychiatric illness is essentially unproven — it is a frontier, not a treatment.

Bottom line

Ablative neurosurgery and focused ultrasound span the most extreme territory in interventional psychiatry. Modern stereotactic ablation — increasingly delivered incisionlessly via MR-guided focused ultrasound — offers meaningful benefit to a minority of the most refractory OCD and depression patients, but its irreversibility and the field's ethical history confine it to true last-resort use under stringent oversight, and where reversible DBS can address the same circuit, it is generally preferred. Low-intensity focused ultrasound is something else entirely: an early-stage but conceptually transformative technology that could one day deliver non-invasive, reversible, anatomically precise modulation of deep brain structures, dissolving the reach-versus-invasiveness trade-off that defines this series. The disciplined stance is restraint toward ablation — last resort, full consent, rigorous review — and patient, skeptical interest in the genuine promise of focused-ultrasound neuromodulation.

Selected references

1. Ballantine HT, et al. Treatment of psychiatric illness by stereotactic cingulotomy. Biol Psychiatry. 1987.
2. Dougherty DD, et al. Prospective long-term follow-up of anterior cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry. 2002.
3. Greenberg BD, et al. Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurg Clin N Am. 2003.
4. Rück C, et al. Capsulotomy for obsessive-compulsive disorder: long-term follow-up of 25 patients. Arch Gen Psychiatry. 2008.
5. Brown LT, et al. Dorsal anterior cingulotomy and anterior capsulotomy for severe, refractory obsessive-compulsive disorder: a systematic review of observational studies. J Neurosurg. 2016.
6. Pepper J, et al. Anterior capsulotomy versus deep brain stimulation for obsessive-compulsive disorder. J Neurosurg. 2015.
7. Kim SJ, et al. Bilateral thermal capsulotomy with MR-guided focused ultrasound for patients with treatment-refractory obsessive-compulsive disorder. Mol Psychiatry. 2018.
8. Jung HH, et al. Bilateral thermal capsulotomy with MR-guided focused ultrasound for refractory obsessive-compulsive disorder: a proof-of-concept study. Mol Psychiatry. 2015.
9. Davidson B, et al. Magnetic resonance-guided focused ultrasound capsulotomy for treatment-resistant psychiatric disorders. Neurotherapeutics. 2020.
10. Elias WJ, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2016.
11. Legon W, et al. Transcranial focused ultrasound modulates the activity of primary somatosensory cortex in humans. Nat Neurosci. 2014.
12. Sanguinetti JL, et al. Transcranial focused ultrasound to the right prefrontal cortex improves mood and alters functional connectivity in humans. Front Hum Neurosci. 2020.
13. Tyler WJ, et al. Transcranial focused ultrasound for neuromodulation. Front Neurosci. 2018.
14. Fini M, Tyler WJ. Transcranial focused ultrasound: a new tool for non-invasive neuromodulation. Int Rev Psychiatry. 2017.
15. Volpini M, et al. The history and future of ablative neurosurgery for major depressive disorder. Stereotact Funct Neurosurg. 2017.
16. Christmas D, et al. Neurosurgery for mental disorder. Adv Psychiatr Treat. 2004.
17. Lipsman N, et al. Neurosurgical treatment of psychiatric disorders. Can J Psychiatry. 2011.
18. Doshi PK. Surgical treatment of obsessive-compulsive disorders: current status. Indian J Psychiatry. 2009.
19. Miller G. Psychiatric neurosurgery — the past and present. Science. 2009.
20. Darmani G, et al. Non-invasive transcranial ultrasound stimulation for neuromodulation. Clin Neurophysiol. 2022.